Lapatinib and gemcitabine for metastatic pancreatic cancer: A phase II study

被引：0
|
作者：
Safran, H.
Miner, T.
Bahary, N.
Whiting, S.
Lopez, C.
Sun, W.
Charpentier, K.
Charpentier, K.
Shipley, J.
Anderson, E.
McNulty, B.
机构：
[1] Brown Univ, Oncol Grp, Providence, RI 02912 USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[6] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15653
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of gemcitabine and Flutamide in advanced pancreatic cancer.
    Mayer, A
    Shaw, J
    D'Ath, S
    Price, P
    Blesing, C
    Corrie, P
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [42] A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
    Basil F. El-Rayes
    Mark M. Zalupski
    Anthony F. Shields
    Ann Marie Ferris
    Ulka Vaishampayan
    Lance K. Heilbrun
    Raghu Venkatramanamoorthy
    Volkan Adsay
    Philip A. Philip
    Investigational New Drugs, 2005, 23 : 583 - 590
  • [43] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Heloisa P. Soares
    Soley Bayraktar
    Marcelo Blaya
    Gilberto Lopes
    Jaime Merchan
    Jessica Macintyre
    Carlos Mayo
    Mark R. Green
    Orlando Silva
    Joe Levi
    Gail Walker
    Caio M. Rocha-Lima
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 839 - 845
  • [44] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Soares, Heloisa P.
    Bayraktar, Soley
    Blaya, Marcelo
    Lopes, Gilberto
    Merchan, Jaime
    Macintyre, Jessica
    Mayo, Carlos
    Green, Mark R.
    Silva, Orlando
    Levi, Joe
    Walker, Gail
    Rocha-Lima, Caio M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 839 - 845
  • [45] A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
    El-Rayes, BF
    Zalupski, MM
    Shields, AF
    Ferris, AM
    Vaishampayan, U
    Heilbrun, LK
    Venkatramanamoorthy, R
    Adsay, V
    Philip, PA
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 583 - 590
  • [46] A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with unresectable or metastatic pancreatic cancer (PC).
    Greeno, E.
    Kindler, H. L.
    Peeters, M.
    Trowbridge, R. C.
    Chong, G.
    Valle, J. W.
    Johnson, B.
    Allain, E. L.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 208S - 208S
  • [47] A phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer
    Ignatiadis, M.
    Polyzos, A.
    Stathopoulos, G. P.
    Tselepatiotis, E.
    Christophyllakis, Ch.
    Argyraki, K.
    Androulakis, N.
    Vardakis, N.
    ANNALS OF ONCOLOGY, 2006, 17 : 311 - 311
  • [48] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    Bassel Fuad El-Rayes
    Philip A. Philip
    Fazlul H. Sarkar
    Anthony F. Shields
    Ann Marie Ferris
    Kenneth Hess
    Ahmad O. Kaseb
    Milind M. Javle
    Gauri R. Varadhachary
    Robert A. Wolff
    James L. Abbruzzese
    Investigational New Drugs, 2011, 29 : 694 - 699
  • [49] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [50] Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: A single center phase II study
    Kanat, O
    Evrensel, T
    Kurt, E
    Demiray, M
    Gonullu, G
    Arslan, M
    Manavoglu, O
    TUMORI, 2004, 90 (02) : 192 - 195
12345